{"": [132, 2102, 0], "Introduction": [2103, 7674, 0], "Research Methodology": [7675, 8867, 0], "SARS-CoV-2 NmAbs and Production Methods": [8868, 13645, 0], "SARS- and MERS-CoV NmAbs with Cross-Activities": [13697, 21071, 0], "Other HCoVs NmAbs with Cross-Activities": [21072, 23624, 0], "Human and Humanized SARS-CoV-2 NmAbs": [23625, 31370, 0], "Non-Human SARS-CoV-2 NmAbs": [31371, 33228, 0], "SARS-CoV-2 NmAbs with Cross-Activity": [33229, 33914, 0], "SARS-CoV-2 NmAb Molecular Neutralizing Activities": [13646, 33914, 1], "Antigenic Epitope and Molecular Action Mechanism": [33915, 40630, 0], "Complementary Biological Diagnostic Test": [40668, 42525, 0], "Possible Improvement of NmAbs Effects": [42526, 43139, 0], "Avoid ADE Effect and Infection Risks": [43140, 45170, 0], "Conserved Sarbecovirus Blocking Sites": [45171, 46913, 0], "Divers NmAbs for Several Blocking Sites": [46914, 47936, 0], "Antibody Cocktails and Treatments": [47937, 57765, 0], "Advantages of anti-SARS-CoV-2 NmAbs": [40631, 57765, 1], "Limit as a Biological Diagnostic Tool": [57778, 58227, 0], "Passive Antibody Therapy": [58228, 58701, 0], "SARS-CoV-2 S Protein Glycan Shields": [58740, 60699, 0], "Molecular Mutations": [60700, 61626, 0], "Virulence and Immune Evasion Factors": [58702, 61626, 1], "Challenges": [57766, 61626, 1], "Discussion": [61627, 67324, 0], "Conclusion": [67325, 70667, 0]}